Quarterly report [Sections 13 or 15(d)]

Acquisition of Vidya Therapeutics, Inc. and Concurrent Private Placement (Tables)

v3.26.3
Acquisition of Vidya Therapeutics, Inc. and Concurrent Private Placement (Tables)
9 Months Ended
Sep. 30, 2026
Asset Acquisition [Abstract]  
Summary of Purchase Price Acquisition

The following summarizes the purchase price paid in the Vidya Acquisition (in thousands, except share and per share amounts):

 

Number of shares of Series A Preferred Stock issued to the Vidya shareholders and option holders, as converted     142,254,972  
Multiplied by the fair value per share of our Series A Preferred Stock(1)   $ 1.22119  
Fair value of Series A Preferred Stock issued to effect the Vidya Acquisition     173,720  
Fair value of the options to purchase Vidya common stock we assumed     1,280  
Purchase Price   $ 175,000  

 

(1) The fair market valuation of the Series A Preferred Stock was determined based on the contractual conversion price per share, on an as-converted basis (1,000 shares of common stock for 1 share of Series A Preferred Stock).

 

The preliminary fair value of the net assets, liabilities, and IPR&D acquired was as follows (in thousands):

 

Cash acquired   $ (102 )
Net liabilities assumed     467  
IPR&D(2)     175,000  
Net liabilities and IPR&D acquired   $ 175,365  

 

(2) Represents the Vidya Acquisition research and development projects which were in process, but not yet completed, and which we may advance following the Vidya Acquisition, including the development of VT-7208. The fair value of IPR&D projects acquired in an asset acquisition with no alternative future use are charged to expense on the acquisition date. Substantially all of the fair value of the gross assets acquired was concentrated in the acquired IPR&D, a single identifiable asset, and the transaction therefore passed the screen test under ASC 805. Accordingly, the acquired set of assets did not meet the definition of a business. Additionally, the acquired assets did not include the outputs or meaningful processes necessary to be considered a business under ASC 805. The IPR&D was recorded at the fair value of the consideration given.